OMG! SOLAGRAN ANNOUNCEMENT!
Key United States Patent Granted for Solagran’s Core Production Technology
Melbourne, Australia: Solagran Limited (ASX: SLA) announces that a key patent protecting
the Company’s core production technology for the manufacture of Bioeffectives®, including
polyprenols / “Bioeffective R†(the major component of Ropren®), has issued in the United
States.
United States Patent No. 8,969,517 entitled “Method for Processing Vegetable Raw
Materials†has corresponding patents already granted in Australia, Russia, Canada,
Indonesia and Latvia, and applications have also been filed in selected other jurisdictions.
Dr Vagif Soultanov, Chairman of Solagran and inventor on the patent with Solagran’s
Professor Viktor Roschin, said “The granting of our core technology patent in the US is a
very important milestone for Solagran. It establishes our proprietary position in the
manufacture from different plant species of high-purity polyprenols and other products
across major jurisdictions, and gives us a firm foundation for future commercial successâ€ÂÂÂÂÂ.
Polyprenols are present in plants in low concentration and are naturally-occurring
precursors of dolichols. Dolichols exist primarily in animals and are found in all key organs
of the human body, playing a major role in crucial metabolic pathways, protecting cellular
membranes, stabilising cell proteins and supporting the body’s immune system. Dolichol
deficit or deficiencies are observed with degenerative diseases including chronic
inflammatory conditions and cognitive disorders.
Importantly, polyprenols can be administered orally and are transformed in the liver to
dolichols. This provides a strong rationale for polyprenol supplementation to potentially
address multiple conditions, including inflammatory diseases, cognitive decline and
multiple liver conditions.
Until development of the Solagran manufacturing process it had not been possible to
extract polyprenols in commercial quantities at reasonable cost. Live conifer needles are
one of the richest and most widely-available sources for polyprenol extraction worldwide.
Solagran uses conifer needles as the starting material for its patented extraction process
and has constructed the world’s first manufacturing facility for the production of
commercial quantities of pharmaceutical grade polyprenols.
Solagran is currently in negotiations to secure distribution for products containing its
proprietary polyprenols in selected countries, and is also preparing registration
documentation for new territories.
About Solagran
Solagran Ltd is a Melbourne-based biotechnology company. It manufactures and markets a
range of unique, efficacious and proprietary products sourced from different species of
conifer trees, targeting the fast-growing natural healthcare and nutraceutical sectors.
Solagran’s competitive advantage in the sector is its long history of scientific excellence,
academic credibility and proprietary manufacturing innovations. The company’s products
range from registered pharmaceuticals, to supplements, nutraceuticals and over-the-counter
products. Solagran products are marketed in Australia, Russia, Malaysia and the UAE, and
additionally registered in Indonesia and Singapore, with negotiations underway to expand
into new territories.
